Global Myasthenia Gravis Treatment Market Size is valued at USD 1.60 Bn in 2024 and is predicted to reach USD 3.34 Bn by the year 2034 at a 7.8% CAGR during the forecast period for 2025-2034.
Myasthenia gravis is an uncommon neuromuscular illness characterized by gradual weakness of the muscles of the face, neck, upper and lower body, and respiratory system. Producing antibodies against the acetylcholine receptor disrupts the regular flow of electrical signals from the nervous system to the muscles in this autoimmune illness. Myasthenia gravis is a condition that causes chronic weakening in the skeletal muscles due to damage to the neuromuscular junction.
Eye, facial, and swallowing muscles are particularly vulnerable. Investigative efforts are currently directed toward elucidating the mechanisms underlying autoimmune issues in MG and developing more effective diagnostic and therapeutic strategies to address them. Researchers have changed their approach as the market shifts its focus from weakening the immune system to rebalancing it. Although symptoms of myasthenia gravis can arise at any age, they tend to become more noticeable in men and women in their generation. Myasthenia gravis has no known treatment.
However, the myasthenia gravis therapy market is limited by the undesirable effects of the current medications. Increased risk of infection, weight gain, mood changes, and gastrointestinal difficulties are only some of the potential negative effects of drugs like corticosteroids and immune suppressants, which can impact patient compliance and limit market expansion. The COVID-19 pandemic has caused widespread chaos in the world's healthcare infrastructure.
The delay between diagnosis and treatment of myasthenia gravis during the epidemic had a major impact on patient outcomes. Doctors often ignored Myasthenia gravis and other non-emergency medical conditions during the epidemic. Delayed diagnosis and treatment may reduce the quality of life for people with myasthenia gravis by allowing the state to grow and worsen. As a result of supply chain problems brought on by the pandemic, players in the myasthenia gravis therapy industry saw their revenue stagnate.
The Myasthenia gravis treatment market is segmented based on treatment and end-use. AS per the treatment, the market is segmented into medication, surgery, and others. The end-use segment consists of hospitals, clinics, and others.
The medication coatings myasthenia gravis treatment market is expected to record a major global market share in 2022 because numerous diseases and ailments are addressed with various medications. Medication benefits include relief of pain, blood pressure reduction, and infectious disease treatment. Medication has dominated the market and will likely continue throughout the projection period. This is due to the fact that drugs can significantly suppress the immune system and control the accompanying symptoms. Treatment options include immunosuppressive medications like tacrolimus and cyclosporine and immunotherapies like Soliris eculizumab.
Hospitals are projected to grow rapidly in the global Myasthenia gravis treatment market due to this increase at a rate faster than any other predicted area. Hospitals have ready access to a big pool of potential patients, and there is a high demand for cutting-edge equipment to treat MG. The increased demand for MG diagnosis and treatment can be attributed to the abundance of available services in specialized clinics. The development of the pharmaceutical contract sales outsourcing market in the hospital's segment has myasthenia gravis market is being driven in large part by these subsets, especially in countries like the US, Germany, the UK, China, and India.
The North American Myasthenia gravis treatment market is expected to register the greatest market share in revenue in the near future. The demand for myasthenia gravis treatments is predicted to grow because of the disease's high incidence, the uptick in autoimmune disease diagnosis, the existence of key firms offering novel medicines, and the availability of modern healthcare infrastructure. In addition, Asia Pacific is estimeted to grow rapidly in the global Myasthenia gravis treatment market. The market is expected a rapid growth due to the region's thriving industrial infrastructure, increasing funding for autoimmune illnesses, and the longstanding presence of domestic corporations. In addition, the region's growing number of contract manufacturing companies presents a significant opening for new businesses.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.60 Bn |
|
Revenue Forecast In 2034 |
USD 3.34 Bn |
|
Growth Rate CAGR |
CAGR of 7.8% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Treatment, By End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Alexion Pharmaceutical Inc, Grifols SA, Avadel Pharmaceuticals plc, Novartis AG, Pfizer, Inc, AbbVie Inc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Bausch Health Companies Inc, Shire plc, AstraZeneca, Novartis AG, Zydus Lifesciences Limited, CSL Limited, Octapharma AG, Astellas Pharma Inc., Kedrion, SpA., and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Myasthenia Gravis Treatment Market Snapshot
Chapter 4. Global Myasthenia Gravis Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Treatment Estimates & Trend Analysis
5.1. By Treatment, & Market Share, 2024 to 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Treatment:
5.2.1. Medication
5.2.2. Surgery
5.2.3. Others
Chapter 6. Market Segmentation 2: By End-Use Estimates & Trend Analysis
6.1. By End-Use & Market Share, 2024 to 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-Use:
6.2.1. Hospitals
6.2.2. Clinics
6.2.3. Others
Chapter 7. Myasthenia Gravis Treatment Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Myasthenia Gravis Treatment Market revenue (US$ Million) estimates and forecasts By Treatment, 2021-2034
7.1.2. North America Myasthenia Gravis Treatment Market revenue (US$ Million) estimates and forecasts By End-Use, 2021-2034
7.1.3. North America Myasthenia Gravis Treatment Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Myasthenia Gravis Treatment Market revenue (US$ Million) By Treatment, 2021-2034
7.2.2. Europe Myasthenia Gravis Treatment Market revenue (US$ Million) By End-Use, 2021-2034
7.2.3. Europe Myasthenia Gravis Treatment Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Myasthenia Gravis Treatment Market revenue (US$ Million) By Treatment, 2021-2034
7.3.2. Asia Pacific Myasthenia Gravis Treatment Market revenue (US$ Million) By End-Use, 2021-2034
7.3.3. Asia Pacific Myasthenia Gravis Treatment Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Myasthenia Gravis Treatment Market revenue (US$ Million) By Treatment, (US$ Million) 2021-2034
7.4.2. Latin America Myasthenia Gravis Treatment Market revenue (US$ Million) By End-Use, (US$ Million) 2021-2034
7.4.3. Latin America Myasthenia Gravis Treatment Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Myasthenia Gravis Treatment Market revenue (US$ Million) By Treatment, (US$ Million) 2021-2034
7.5.2. Middle East & Africa Myasthenia Gravis Treatment Market revenue (US$ Million) By End-Use, (US$ Million) 2021-2034
7.5.3. Middle East & Africa Myasthenia Gravis Treatment Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Alexion Pharmaceutical Inc.;
8.2.2. Grifols SA;
8.2.3. Avadel Pharmaceuticals plc. Novartis AG;
8.2.4. Pfizer; Inc.;
8.2.5. AbbVie Inc.;
8.2.6. F. Hoffmann-La Roche Ltd.;
8.2.7. GlaxoSmithKline plc;
8.2.8. Bausch Health Companies Inc.;
8.2.9. Shire plc.
8.2.10. Other Players
Myasthenia Gravis Treatment Market By Treatment -
Myasthenia Gravis Treatment Market By End-Use
Myasthenia Gravis Treatment Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
